In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Idenix Pharmaceuticals closes $58mm IPO

Executive Summary

Infectious and viral disease therapeutics company Idenix Pharmaceuticals (majority owned by Novartis) has completed its initial public offering, selling 4.6mm common shares at $14 apiece. Selling stockholders also sold 1.2mm shares.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies